Transcranial Ultrasound in Clinical SONothrombolysis (TUCSON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00504842
Recruitment Status : Terminated (Sponsor decision)
First Posted : July 20, 2007
Last Update Posted : April 15, 2008
Information provided by:
ImaRx Therapeutics

July 18, 2007
July 20, 2007
April 15, 2008
December 2006
Not Provided
Incidence of symptomatic intracranial hemorrhage [ Time Frame: 36 hours ]
Same as current
Complete list of historical versions of study NCT00504842 on Archive Site
  • Rate of recanalization of occluded artery [ Time Frame: 120 minutes ]
  • Independent outcome (modified Rankin Scale 0-2) [ Time Frame: 90 days ]
Same as current
Not Provided
Not Provided
Transcranial Ultrasound in Clinical SONothrombolysis
A Phase 1-2, Randomized, Placebo-Controlled, Single-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Activity of Ascending Single Doses of MRX-801 With Continuous Ultrasound Administration in Subjects With Acute Ischemic Stroke Receiving Treatment With Intravenous Tissue Plasminogen Activator
This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.
Not Provided
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Acute Ischemic Stroke
  • Drug: MRX-801
  • Drug: Placebo
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
March 2008
Not Provided

Inclusion Criteria:

  • Acute ischemic stroke
  • Occlusion demonstrated by transcranial Doppler ultrasound
  • Eligible for tPA

Exclusion Criteria:

  • Right to left cardiac shunt
  • Moderate to severe COPD
  • Uncontrolled hypertension
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
France,   United States
Not Provided
Not Provided
Not Provided
ImaRx Therapeutics
Not Provided
Study Director: Carlos Molina Cateriano, MD University Hospital Vall d'Hebron, Barcelona, Spain
ImaRx Therapeutics
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP